Guatemala vs New Zealand: Hepatitis B surface antigen (HBsAg) prevalence
Guatemala
0.0%
in 2024
New Zealand
0.0%
in 2024
Guatemala rank
132nd
New Zealand rank
132nd
Hepatitis B surface antigen (HBsAg) prevalence over time
- Guatemala
- New Zealand
How they compare
Guatemala currently reports 0.0% against 0.0% in New Zealand, a difference of 0.0%.
The two have swapped places 2 times across 10 shared years of data; in 2015 it was New Zealand ahead.
Guatemala ranks 132nd and New Zealand ranks 132nd of 194 countries.
Guatemala has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Guatemala | New Zealand | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.1% | 0.0% | Guatemala |
| 2020s | 0.0% | 0.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Guatemala or New Zealand?
- Guatemala, at 0.0% against 0.0% in New Zealand as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Guatemala and New Zealand?
- 0.0%, with Guatemala ahead.
- How many years of comparable data are there for Guatemala and New Zealand?
- 10 years are reported by both, from 2015 to 2024.
- How do Guatemala and New Zealand rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Guatemala ranks 132nd and New Zealand ranks 132nd of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.